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Attenuates the Acceleration of
Gastric Emptying Induced by
Hypoglycemia in Healthy Subjects
Diabetes Care 2014;37:1509–1515 | DOI: 10.2337/dc13-1813
OBJECTIVE
Exogenous GLP-1 slows gastric emptying in health and diabetes leading to dimin-
ished glycemic excursions. Gastric emptying is markedly accelerated by hypogly-
cemia. The primary objective was to determine whether GLP-1 attenuates the
acceleration of gastric emptying induced by hypoglycemia.
RESEARCH DESIGN AND METHODS
Ten healthy volunteers were studied on four separate days in a randomized
double-blind fashion. Blood glucose was stabilized using a glucose/insulin
clamp at hypoglycemia (2.6 mmol/L on two occasions [hypo]) or euglycemia
(6.0 mmol/L on two occasions [eu]) between T =215 and 45 min before clamping
at 6.0 mmol/L until 180 min. During hypoglycemia and euglycemia, subjects re-
ceived intravenous GLP-1 (1.2 pmol/kg/min) or placebo. At T = 0 min, subjects
ingested 100 g beef mince labeled with 20 MBq 99mTc-sulfur-colloid and 3 g of
3-O-methyl-glucose (3-OMG), a marker of glucose absorption. Gastric emptying
was measured scintigraphically from T = 0 to 180 min and serum 3-OMG taken
at 15-min intervals. The areas under the curve for gastric emptying and 3-OMG
concentration were analyzed using one-way repeated-measures ANOVA with
Bonferroni-Holm adjusted post hoc tests.
RESULTS
Gastric emptying was accelerated during hypoglycemia (hypo/placebo vs.
eu/placebo; P < 0.001), aswas glucose absorption (P< 0.03). GLP-1 slowed emptying
during euglycemia (eu/placebo vs. eu/GLP-1; P < 0.001). However, hypoglycemia-
induced acceleration of gastric emptying on placebo was markedly diminished by
GLP-1 (hypo/placebo vs. hypo/GLP-1; P < 0.008), as was glucose absorption
(P < 0.01).
CONCLUSIONS
Acute administration of exogenous GLP-1 attenuates, but does not abolish, the
acceleration of gastric emptying by insulin-inducedhypoglycemia inhealthy subjects.
Glucagon-like peptide 1 (GLP-1) receptor agonists are now incorporated into stan-
dard treatment algorithms for themanagement of type 2 diabetes (1). Several GLP-1
receptor agonists are available and are increasingly used as monotherapy, as second-
line therapy (particularly with metformin and/or sulphonylurea), and, more recently,
in combination with basal insulin (1,2).
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The development of GLP-1 agonists
was stimulated by characterization of
the effects of exogenous GLP-1 to lower
both fasting and postprandial glycemia
(3). During fasting, the glucose-lowering
effect of GLP-1 is predominantly medi-
ated through effects on islet cell func-
tion to increase insulin and reduce
glucagon secretion in a glucose-dependent
manner (4,5). Accordingly, GLP-1 and
its agonists are extremely unlikely to
cause hypoglycemia when used as
monotherapy.
In contrast to the fasted state, during
the postprandial phase, glucose lower-
ing by acute administration of GLP-1 is
mediated primarily through its effect to
slow gastric emptying (6). Indeed, post-
prandial insulin concentrations are re-
duced by administration of GLP-1
because of the delayed entry of nu-
trients into the small intestine (6). This
also appears to be the case with “short-
acting”GLP-1 agonists such as exenatide
BD (7) and lixisenatide (8), which have a
sustained effect to slow gastric empty-
ing. Additionally, because the human
stomach empties at an overall rate of
1–4 kcal/min in health (9), most humans
are predominantly in the postprandial
state with the duration of fasting limited
to ;4 h before breakfast (10). Hence,
the effect of GLP-1 and its agonists of
slowing gastric emptying is of funda-
mental signiﬁcance and provides a per-
suasive rationale for their combination
with basal insulin, given that this ap-
proach targets both fasting and post-
prandial glycemia and doesn’t lead to
weight gain (10).
Given that GLP-1 agonists may be
combined with a sulphonylurea or
insulin, there is, however, the potential
for hypoglycemia. For this reason, it is
reassuring that in health, pharmacolog-
ical doses of GLP-1 have no effect on the
counterregulatory hormonal response
to insulin-induced hypoglycemia (5).
Somewhat surprisingly, however, the ef-
fect of GLP-1 on gastric emptying during
hypoglycemia has not been evaluated.
Acute glycemia per se is a major de-
terminant of the gastric-emptying rate,
and hypoglycemia potently accelerates
gastric emptying in both healthy subjects
(11) and patients with type 1 diabetes
(12). Conversely, marked hyperglycemia
slows gastric emptying (13,14), and
even glycemic perturbations that are
within the normal physiological range in-
ﬂuence gastric emptying in health and
patients with type 1 diabetes (14). In-
deed, systemic glycemia has been shown
to alter the effect of gastrokinetic drugs;
for example, hyperglycemia potently at-
tenuates the gastrokinetic effect of
erythromycin (15). However, the interac-
tion of hypoglycemia with drugs that
slow gastric emptying has not yet been
investigated in humans.
The acceleration of gastric emptying
during hypoglycemia is likely to be a
physiological protective mechanism
that increases delivery and absorption
of carbohydrate. Indeed, the current
American Diabetes Association guide-
lines for the treatment of hypoglycemia
emphasize the importance of carbohy-
drate ingestion (16). While the insulino-
tropic and glucagonostatic effects of
GLP-1 and its agonists are established
as glucose dependent, the effect of hy-
poglycemia on the GLP-1–induced slow-
ing of gastric emptying is unknown. This
is of particular importance considering
the interest in combinations of GLP-1
agonists and basal insulin, which may
increase the risk of hypoglycemia when
compared with GLP-1 monotherapy.
The primary aim of this study was to de-
termine whether GLP-1 attenuates the
acceleration of gastric emptying in-
duced by acute hypoglycemia in health.
RESEARCH DESIGN AND METHODS
Subjects
Healthy volunteers aged 50–75 years
were eligible, and those with diabetes
(HbA1c .6.5%; 48 mmol/mol), BMI
$30 kg/m2, impaired renal function or
anemia, currently smoking, consuming
.20 g/day of alcohol, receiving medica-
tion known to affect gastrointestinal
motility or glycemia, or with a history
of gastric or small intestinal surgery
were excluded.
Protocol
All subjects were studied in random or-
der on four separate occasions sepa-
rated by a minimum of 4 days (Fig. 1).
Each subject underwent concurrent
measurements of gastric emptying,
blood glucose concentrations, and
glucose absorption on each of the four
occasions: twice with blood glucose con-
centrations maintained at euglycemia
(blood glucose of 6 mmol/L (108 mg/dL)
[eu]) and twice with a period of insulin-
induced hypoglycemia (blood glucose of
2.6 mmol/L [47 mg/dL] [hypo]) (Figs. 1
and 2). Randomization was performed
by the Department of Pharmacy at the
Royal Adelaide Hospital, which notiﬁed
study investigators M.P.P., C.E.A., and
C.E.C. of the glucose targetona particular
Figure 1—Schematic representation of the study protocol. Blood glucose concentrations (BG) were stabilized using a glucose/insulin clamp at
hypoglycemia (2.6mmol/L; BG 1) or euglycemia (6.0mmol/L; BG2) between T =215 and 45min before clamping at 6.0mmol/L until 180min. During
hypoglycemia and euglycemia, subjects received intravenous GLP-1 (1.2 pmol/kg z min) or placebo between T = 260 and 180 min. At T = 0 min,
subjects ingested a labeled meal. Gastric emptying was measured scintigraphically from T = 0 to 180 min, and serum 3-OMG concentrations were
taken at 15-min intervals for the ﬁrst hour and then half hourly until study completion.
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study day. These investigators played no
role in analysis of gastric-emptying data.
Randomization of study drug, either
GLP-1 or placebo, was also performed
by the Department of Pharmacy, and al-
location of the study drug was concealed
to all investigators throughout the study.
Either GLP-1 (1.2 pmol/kg/min) or pla-
cebo (0.9% saline) was administered in-
travenously during both euglycemia
and hypoglycemia.
Each subject attended the Depart-
ment of Nuclear Medicine, Positron
Emission Tomography, and Bone Densi-
tometry at the Royal Adelaide Hospital
at 0830 h after an overnight fast. Two
intravenous cannulaewere inserted into
the right arm: one in the antecubital
vein for an infusion of insulin and 25%
dextrose and another in the dorsal vein
of the right hand for infusion of study
drug. A third intravenous cannula was in-
serted into the left antecubital vein for
blood sampling. Synthetic GLP-1 amide
(Bachem, Weil am Rhein, Germany) was
reconstituted by the Department of Phar-
macy in 0.9%normal saline. After drawing
of baseline blood specimens, both GLP-1
(1.2 pmol/kg/min) and placebo (0.9% sa-
line) infusions were commenced 60 min
prior to meal ingestion and infused at a
rate of 1 mL/min for the duration of the
study (i.e., T =260 to 180 min) (17). The
infusion rate of 1.2 pmol/kg/min was
based on previous studies and was
known to raise plasma GLP-1 concentra-
tions into the pharmacological range
(approximately three- to fourfold higher
concentrations in comparisonwith those
measured after oral glucose) (5,18,19)
and is representative of GLP-1 receptor
stimulation that occurs during admin-
istration of commercial agonists (4,20).
An insulin-glucose clamp was started
30 min later as described below. After
blood glucose concentrations had been
stabilized at the desired level for 15 min,
subjects consumed the test meal within
5 min.
The study protocol was approved by
the Royal Adelaide Hospital Human Re-
search Ethics Committee and registered.
Written informed consent was obtained
from all subjects prior to their inclusion.
Stabilization of Blood Glucose
Concentrations
An insulin-glucose clamp was started at
T = 230 min with a continuous infusion
of human insulin (Actrapid; Novo Nor-
disk Pharmaceuticals, Auckland, New
Zealand). Insulin (50 IU) was drawn up
into 50 mL normal saline. The protocol
was modiﬁed from a hypoglycemic
clamp algorithm administered to pa-
tients with type 1 diabetes (12). The
infusion for the current study was com-
menced at 125mU/m2 per min and then
titrated over 10 min to a maintenance
rate of 40 mU/m2 per min. A 25% dex-
trose infusion was given simultaneously
at a varying rate to maintain the blood
glucose at the desired level (12). On the
euglycemic study days, blood glucose
was maintained at 6.0 mmol/L (108
mg/dL) from T =230min to the comple-
tion of the study at T = 180min with 25%
dextrose infused at rates of 50–200mL/h.
During the hypoglycemic studies, the
blood glucose was stabilized at 2.6
mmol/L (47 mg/dL) with infusion of
25% glucose at rates of 0–12 mL/h for
15 min prior to meal ingestion and
then maintained at this blood glucose
concentration for a further 45 min after
completion of the meal (12). The blood
glucose was then titrated to 6.0 mmol/L
over a 30-min period (i.e., to T = 75 min)
and maintained at 6.0 mmol/L for the
remainder of the study (Fig. 2).
Starting immediately before the com-
mencement of the insulin-glucose
clamp, venous blood samples for mea-
surement of glucose were taken every
5 min until T = 90 min and then every
15 min until study completion at T =
180 min. Blood glucose concentrations
were measured using a portable glucose
meter (Optium Xceed; Abbott Laborato-
ries, Bedford, MA) (12).
Measurement of Gastric Emptying
The test meal comprised 100 g lean
minced beef, labeled with 20 MBq 99mTc-
sulfur-colloid (Pharmalucence, Inc., Bed-
ford, MA) (12) and 3 g 3-O-Methyl-D-
glucopyranose (3-OMG) (Sigma-Aldrich,
Sydney, Australia) dissolved in 150 mL
water. The solid meal was consumed
over 5 min, followed by ingestion of
the 3-OMG–labeled water. Scintigraphic
Figure 2—Blood glucose concentrations. Blood glucose (mmol/L) was stabilized using a glucose/insulin clamp at hypoglycemia (2.6 mmol/L) or euglycemia
(6.0 mmol/L) between T =215 and 45 min before clamping at 6.0 mmol/L until 180 min. Data are presented as mean (SE). BGL, blood glucose level.
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datawere acquiredwith a g camera (Dig-
irad, Poway, CA) placed over the abdo-
men of the participant to obtain a left
anterior oblique image. Subjects were
lying in a supine position with the upper
body at an angle of ;30 degrees. Data
were acquired from meal completion
(T = 0 min) in 1-min frames for 180 min
and corrected for radionuclide decay,g-ray
attenuation (using the left anterior oblique
view), and subject movement (15). Ra-
dioisotopic data were analyzed by a nu-
clear medicine scientist (K.L.J.) who was
not present during studies and remained
blinded to both the treatment arm and
the glycemic period assigned. A region of
interest was drawn around the total
stomach, and a gastric-emptying curve,
expressed as total retention over time,
was derived from this region (15).
Measurement of Glucose Absorption
Serum 3-OMG was used as an index of
intestinal glucose absorption (21,22)
and was measured using liquid chroma-
tography/mass spectroscopy, with an
assay sensitivity of 0.0103 mmol/L
(22). After the test meal, blood was col-
lected at T = 15, 30, 45, 60, 90, 120, 150,
and 180 min and, once clotted, centri-
fuged at 3,200 rpm for 15 min. Serum
was then stored at2708C for subsequent
measurement of 3-OMG concentrations,
with the rate of glucose absorption indi-
cated by the area under the 3-OMG con-
centration curve (AUC) (22).
Statistical Analysis
Power calculations were performed us-
ing our data relating to the effect of ex-
ogenous GLP-1 on gastric emptying in
health (23). Overall effects for both
gastric emptying and 3-OMG absorption
were calculated as AUC0–180. Given the
strict hypoglycemic period occurred in
the ﬁrst 45 min (AUC0–45), this period
was also predeﬁned as of interest. Data
were evaluated using one-way repeated-
measures ANOVA, with Bonferroni
Holm adjusted post hoc tests for multi-
ple comparisons. Data are shown as
mean 6 SEM, with the difference be-
tween groups (Δ) reported as mean
(SD). Given that we have reported an
association between glucose absorption
and gastric emptying (21,22), we tested
for this relationship. This correlation was
evaluated adjusted for repeated mea-
sures (24). The null hypothesis was re-
jected at the 0.05 signiﬁcance level.
Statistical analyses were performed using
SPSS (version 16.0; SPSS, Chicago, IL). All
analyses were supervised by an indepen-
dent professional biostatistician.
RESULTS
All of the subjects tolerated the study
without adverse effects. During hypo-
glycemia, all volunteers experienced a
range of moderate symptoms including
sweating, palpitations, and visual distur-
bance, but there were no major adverse
events. One patient experienced mild
nausea with GLP-1 during a euglycemic
study day. Blood glucose concentrations
were effectively clamped at hypoglycemic
and euglycemic targets on both GLP-1
(2.7 6 0.03 and 5.86 0.05 mmol/L) and
placebo (2.8 6 0.04 and 5.9 6 0.03
mmol/L) study days (Fig. 2).
Tomaintain the glycemic clamps, sub-
stantially less (intravenous) dextrose
was required during hypoglycemia
compared with euglycemia (hypo/pla-
cebo vs. eu/placebo, Δ36 (11) g; P =
0.018). GLP-1 increased intravenous dex-
trose required during euglycemia (eu/
GLP-1 vs. eu/placebo, Δ25 (6) g; P ,
0.01) and hypoglycemia (hypo/GLP-1 vs.
hypo/placebo, Δ23 (8) g; P = 0.03).
Solid Gastric Emptying
Gastric retention (%) over time is shown
in Fig. 3. The initial ANOVA for all four
curves was signiﬁcant at both 45 (P =
0.003) and 180 (P , 0.001) min. Gastric
retention was less during hypoglycemia
at both 45 min (AUC0–45, hypo/placebo
vs. eu/placebo; P , 0.01) and overall
(AUC0–180, P , 0.001), consistent with
more rapid gastric emptying. Adminis-
tration of exogenous GLP-1 increased
gastric retention during euglycemia
(AUC0–180, eu/placebo vs. eu/GLP-1;
P , 0.001) consistent with a profound
slowing of gastric emptying. Despite
GLP-1 administration, the induction of
hypoglycemia accelerated gastric emp-
tying at 45 and 180 min (hypo/GLP-1 vs.
eu/GLP-1: AUC0–45, P = 0.03, and AUC0–180,
P, 0.01). However, during hypoglycemia
GLP-1 slowed gastric emptying at 180 min
compared with placebo (AUC0–180, hypo/
placebo vs. hypo/GLP-1; P , 0.008) but
not at 45 min (AUC0–45, P = 0.10).
Serum 3-OMG Concentrations
Serum 3-OMG concentrations are
shown in Fig. 4. The initial ANOVA for
all four curves was signiﬁcant at both
45 and 180 min (P, 0.001). During pla-
cebo and hypoglycemic GLP-1 studies,
there was an initial linear rise in 3-OMG
concentration tapering to a peak at
60 min followed by a gradual linear
Figure 3—Gastric retention. Gastric retention (%) of test meal in 10 healthy volunteers with blood glucose clamped at either hypoglycemia
(2.6 mmol/L) or euglycemia (6.0 mmol/L) with or without GLP-1 (1.2 pmol/kg z min i.v.). Data are presented as mean (SE).
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decline. In contrast, during euglycemic
GLP-1 studies there was minimal
3-OMG absorption over the ﬁrst 30 min
with a mild rise to 60 min, which then
plateaued for the remainder of the stud-
ies. Overall, hypoglycemia increased
3-OMG concentrations, (AUC0–180,
hypo/placebo vs. eu/placebo; P = 0.03).
However, GLP-1 markedly reduced 3-
OMGconcentrations during hypoglycemia
(hypo/placebo vs. hypo/GLP-1; AUC0–45,
P = 0.02; and AUC0–180, P , 0.01), as
well as during euglycemia (AUC0–180,
eu/placebo vs. eu/GLP-1; P , 0.001).
Relationships Between Glucose Absorption
and Gastric Emptying
There was a strong association be-
tween 3-OMG absorption and gastric
emptying (AUC0–180% retention and
AUC0–180 3-OMG; r =20.81, P, 0.001).
CONCLUSIONS
The key ﬁnding of this study is that in
health, exogenousGLP-1 (1.2pmol/kg/min)
administered acutely attenuates the ac-
celeration of gastric emptying secondary
to insulin-induced hypoglycemia and,
thereby, the rate of small intestinal car-
bohydrate absorption.
It is established that hypoglycemia
markedly accelerates gastric emptying
in healthy subjects (11) and patients
with insulin-dependent diabetes (12).
The magnitude of the acceleration of
emptying that we observed during hy-
poglycemia was consistent with these
previous studies, and while the exact
mechanism(s) underlying this effect is
incompletely understood, vagal stimula-
tion appears to be important (25).
Furthermore, it is unequivocally es-
tablished that acute administration of
GLP-1 at pharmacological doses pro-
foundly slows gastric emptying at “nor-
mal” blood glucose concentrations in
health and patients with diabetes
(18,23,26). While the underlying mech-
anisms also remain to be fully eluci-
dated, vagal cholinergic pathways
(3,27) and direct centrally mediated ef-
fects (28) are probably important.
While the islet cell effects of GLP-1
are glucose dependent, such that with
increasing blood glucose concentrations
the insulinotropic effects are more pro-
nounced (29), during hypoglycemia the
secretion of the counterregulatory hor-
mones are unaffected by GLP-1 (5).
Nauck et al. (5) reported that during in-
sulin-induced hypoglycemia (2.3 mmol/L)
glucagon, catecholamines, and cortisol
concentrations were the same regard-
less of whether exogenous GLP-1 (1.2
pmol/kg/min) or placebo was infused.
Similar results have been reported using
the commercial GLP-1 agonists exena-
tide and liraglutide at therapeutic con-
centrations in both health and type 1
diabetes (30,31). Furthermore, in health,
GLP-1 and exenatide have no effect on
C-peptide concentrations during insulin-
induced hypoglycemic clamp conditions
(5,30). Accordingly, during hypoglycemia
even pharmacological doses of GLP-1
have no effect on islet cell secretion.
This is the ﬁrst study to evaluate the ef-
fect of a drug that slows gastric emptying
during hypoglycemia in humans. A par-
ticular strength of our study is that we
achieved glucose concentrations during
hypoglycemia that are below the glyce-
mic threshold for the glucagon and epi-
nephrine counterregulatory response in
older adults and comparable with a
“severe” hypoglycemic episode in the
community (32). At these glucose
concentrations, and in contrast to the
glucose-dependent b-cell response de-
scribed above, we observed that dur-
ing severe hypoglycemia (2.6 mmol/L),
GLP-1 continued to slow gastric emp-
tying, albeit less potently than during
euglycemia.
The mechanism(s) underlying the ef-
fect observed in our study can only be
speculated upon. It is possible that GLP-
1–induced slowing of gastric emptying
and retardation of delivery of carbohy-
drate to the small intestine share the
same efferent vagal pathways as the
“normal physiological” response to hy-
poglycemia, which is to accelerate gas-
tric emptying and increase delivery of
carbohydrate to the small intestine
(11). Accordingly, the effects on gastric
emptying that we observed in health
may not be reproducible in patients
with autonomic dysfunction. However,
it should also be recognized that the ac-
celeration of gastric emptying by insulin-
induced hypoglycemia is still evident in
patients with type 1 diabetes who have
autonomic dysfunction (12). Further
animal or human studies using speciﬁc
cholinergic antagonists will be re-
quired to deﬁne the exact contribution
of peripheral and central mechanisms
(27,33,34).
Although the incretin-based thera-
pies have an inherently low risk of
Figure 4—Glucose absorption (serum 3-OMG concentrations). Serum 3-OMG (mmol/L) concentrations in 10 healthy volunteers with blood glucose
clamped at either hypoglycemia (2.6 mmol/L) or euglycemia (6.0 mmol/L) with or without GLP-1 (1.2 pmol/kg z min i.v.). Data are presented as
mean (SE).
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hypoglycemia, our ﬁndings may have
important safety implications in pa-
tients for whom GLP-1 agonists are pre-
scribed as “add-on” therapy to a
sulphonylurea or basal insulin. While
these combinations with GLP-1 agonists
are associated with a low risk of hypo-
glycemia (35), our data highlight that
the subsequent management of hypo-
glycemia, should it occur, is potentially
problematic. Indeed, our ﬁndings re-
lated to gastric emptying and glucose
absorption suggest that the response
to treatment of hypoglycemia with car-
bohydrate ingestion will be delayed in
these patients. While only a trend to-
ward attenuation of solid gastric empty-
ing was observed during GLP-1 and
the “strict” hypoglycemic clamp period
(0–45mins), the end point of primary
clinical relevance is small intestinal glu-
cose absorption, which was substan-
tially reduced compared with placebo
on the hypoglycemic days on GLP-1 at
both 45 min and for the duration of the
study period. While we urge against
overinterpreting these data, the obser-
vation that GLP-1 slows gastric emptying
even during hypoglycemia may have im-
plications for the prescription of other
drugs that inﬂuence gastric emptying,
such as opiates (36), when coadminis-
tered to patients who are receiving in-
sulin. Studies of these other agents are
now required.
There are, however, limitations to our
study. We elected to evaluate the ef-
fects of GLP-1 on the response to hypo-
glycemia in subjects that were not
diabetic, as patients with diabetes
have the potential for abnormally slow
gastric emptying at baseline (37), and it
is known that the effect of GLP-1 to slow
gastric emptying is dependent on the
underlying rate of emptying (22). The
effect of hypoglycemia on gastric emp-
tying in patients with type 2 diabetes is
yet to be fully elucidated, but the hor-
monal counterregulatory response is
similar, albeit occurring at higher blood
glucose concentrations when compared
with health (38), so the effect on gastric
emptying is unlikely to be diminished.
A continuous infusion of synthetic GLP-1
wasadministeredat a representativephar-
macological concentration rather than
subcutaneous administration of a com-
mercially available GLP-1 agonist. This en-
sured predictable GLP-1 concentrations,
but the response to the commercially
available drugsmay not be so consistent.
Furthermore, the study design was, of
necessity, somewhat “artiﬁcial” so that
the effects in patients may potentially
differ from those observed using a sus-
tained period of hyperinsulinemic hypo-
glycemia and a predominantly protein
“meal.” This, of course, does not reﬂect
clinical practice where hypoglycemia is
treated with a carbohydrate load and
the blood glucose allowed to normalize.
It is reassuring that in large clinical trials
of combined GLP-1 receptor agonist and
basal insulin, the occurrence of severe
hypoglycemia (loss of consciousness, sei-
zure, or hypoglycemia requiring third-
party intervention) has been very low
(0.0–2.5%) (2,39). The extent to which
ﬁndings account for the low but variable
rate of minor hypoglycemia (4–53%)
(2,39) is unknown and warrants further
investigation.
In conclusion, this study establishes
that acute administration of exogenous
GLP-1 attenuates, but does not abolish,
the acceleration of gastric emptying
induced by hypoglycemia in healthy
subjects. This is in contrast to the well-
documented glucose-dependent glu-
cose-lowering effects of GLP-1 on the
pancreatic islet cells. Our data highlight
the potential safety implications for the
combination of GLP-1 agonists with
agents known to induce hypoglycemia,
in particular sulphonylureas and insulin.
Our observations support ongoing eval-
uation of the gastrokinetic properties of
GLP-1 and its commercially available ag-
onists during hypoglycemia in patients
with type 2 diabetes.
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